In vitro assays are useful for large-scale oncology compound screening , including efficacy and target engagement assessment, and biomarker discovery and validation.
To fully understand vast in vitro datasets and maximize translatability, analysis by qualified experts is key. Advanced analysis of such high throughput screening data allows you to effectively choose which candidates to move forward with confidence.
Dr. Sheng Guo is Head of Bioinformatics at Crown Bioscience since 2011. Dr. Guo previously worked at Syngenta and Boehringer Ingelheim. His current interests are tumor model genomics, preclinical statistics, biomarker discovery, NGS product design, and industrial software development. Dr. Guo received his Ph.D. in Genomics and Computational Biology from the University of Pennsylvania, and B.S. in Biochemistry from Nankai University. Dr. Guo has authored more than 50 abstracts and manuscripts.